Bulk Drugs Manufacturers Association

What Bulk Drugs Manufacturers Association does

Bulk Drugs Manufacturers Association (BDMAI) is a not-for-profit industry body founded in 1991 and headquartered in Hyderabad, India, representing manufacturers of active pharmaceutical ingredients (APIs) and bulk drugs in the Indian pharmaceutical sector. The association functions as the collective advocacy and service-delivery platform for its member companies, engaging directly with central regulators (CDSCO, DCGI, DGFT), state drug controllers, and the Department of Pharmaceuticals on policy, quality, and trade matters affecting bulk drug manufacturers. Its service stack includes the BDMA Training & Testing (T&T) Centre for skill development, a Resource Centre for technical and regulatory reference materials, and a member-facing digital infrastructure for communication and representation.

BDMAI's core offerings combine policy advocacy, technical training, and member services. The BDMA T&T Centre delivers structured training programs for industry personnel, while the newly launched e-Marketing Portal (June 2025) extends the association's role into digital commercial enablement for its member base. Member companies include leading Indian API and formulation manufacturers (such as Aurobindo Pharma, Hetero Drugs, MSN Laboratories, and others), giving BDMAI representational breadth across the bulk drug value chain. The association maintains standing technical collaborations with bodies including USP India, LSSSDC, C-DAC, IICT, CPCB, and the Telangana Council of Higher Education, which it leverages to support member capability-building and regulatory submissions.

BDMAI is funded primarily through membership subscriptions and training/program fees rather than commercial product revenue. Its go-to-market model is member-recruitment and retention — adding and servicing manufacturers operating in APIs, intermediates, and related bulk drug categories. Customer (member) segments skew toward mid-to-large Indian generic and API manufacturers, with representation also from ancillary service providers and academic partners. The association does not disclose financials publicly, and its commercial scale is best understood in terms of membership breadth, regulatory influence, and the volume of training and representation activity rather than revenue.

Name

Bulk Drugs Manufacturers Association

Legal name

Bulk Drug Manufacturers Association (India)

Website

https://bdmai.org

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

11–50 employees

Short description

Bulk Drugs Manufacturers Association (BDMAI) is a Hyderabad-based not-for-profit industry body, founded in 1991, that represents India's API and bulk drug manufacturers, providing policy advocacy, regulatory representation, technical training, and member services.

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Association

NAICS

Business Associations (813910)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Pharmaceutical industry association
• API manufacturer advocacy
• Bulk drug representation
• Pharma regulatory compliance
• Industry training services

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Distribution channels2 records

Marketing channels5 records

Core offering

BDMAI is an industry association representing bulk drug (API) manufacturers across India. Its core offerings include policy advocacy to central and state governments, regulatory compliance guidance, technology and training through the BDMA T&T Centre, and an e-Marketing Portal facilitating business connections for member companies.

Product overview

BDMAI is an industry association that provides a suite of member services including an e-Marketing Portal for promoting Indian bulk drugs, a Technology & Training Centre (T&T Centre) for skill development and QC manpower training, a Resource Centre with import/export data and technical resources, and a Government Schemes portal for PLI, PRIP, and other government incentive programs. The e-Directory facilitates vendor registration. BDMAI does not manufacture products but serves as a coordination and advocacy body for India's bulk drug (API) manufacturers.

Differentiator

Problem solved

Functional benefit

Products and services

• e-Marketing Portal An online platform launched by BDMAI to promote the Indian bulk drug industry, enabling member companies to market their APIs, intermediates, and related products to international buyers.
• BDMA T&T Centre (Technology and Training Centre) A technology and training center operated by BDMAI at Jeedimetla, providing skill development, QC manpower training, and industry-relevant programs in collaboration with DDUGKY and EGMM Telangana.
• Resource Centre A repository of industry resources including import/export data by country and HS code, USP monographs, ICH guidelines, technical articles, and regulatory documents.
• Government Schemes & Notifications Portal Information portal covering PLI (Production Linked Incentive) scheme, PRIP (Promotion of Research & Innovation in Pharma MedTech) scheme, SPI (Strengthening of Pharmaceutical Industries) scheme, MOOWR scheme, and government notifications on regulations like Schedule M revision.
• e-Directory A directory service enabling registration of vendors and service providers for the bulk drug manufacturing ecosystem.

Quantifiable outcome

• 34th AGM conducted in September 2025 with participation from Dr. GV Prasad of Dr. Reddy's Labs

Named customers10 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Nine partnerships are on record, tiered core and major.

• Telangana Council of Higher Education (TGCHE)coreStrategic or Co-development Partner · 8 February 2025MoU signed on 8th February 2025 for industry-academia collaboration. Aims to bridge the gap between pharmaceutical industry requirements and academic training, facilitating skill development and research collaboration for BDMAI member companies.
• United States Pharmacopeia (USP) IndiacoreStrategic or Co-development PartnerRegular interactions between USP India team and BDMAI member companies for quality standards, monograph development, and regulatory guidance. Meetings conducted at BDMA T&T Centre.
• CDSCO (Central Drugs Standard Control Organization)coreStrategic or Co-development PartnerCDSCO conducts online demonstrations and training for Schedule M implementation and WHO GMP/COPPs applications through ONDLS portal, facilitated by BDMAI for member companies.
• USFDA India TeammajorStrategic or Co-development PartnerRegular industry interactions and meetings with USFDA India team to help member companies understand regulatory requirements and compliance expectations.
• Department of Pharmaceuticals, Government of IndiacoreStrategic or Co-development PartnerBDMAI coordinates PRIP (Promotion of Research & Innovation in Pharma MedTech) scheme for member companies, facilitating access to government R&D funding and innovation support.
• LSSSDC (Life Sciences Sector Skill Development Council)majorStrategic or Co-development PartnerFree in-house upskilling programmes for employees of BDMAI member companies, providing skill development in pharmaceutical manufacturing.
• C-DAC (Centre for Development of Advanced Computing)majorTechnology or IntegrationC-DAC team engaged with BDMAI for ONDLS portal development for WHO GMP/COPPs applications, facilitating digital transformation of regulatory submissions.
• IICT (Indian Institute of Chemical Technology)majorStrategic or Co-development PartnerBDMA IICT Sample Collection Centre launched for industry testing and research support services.
• CPCB (Central Pollution Control Board)majorStrategic or Co-development PartnerDemonstration and consultation sessions on Unified Consent and Authorization Management System (UCAMS) and OCEMS portal for environmental compliance.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• International Generic and Biosimilar Medicines Association (IGBA): IGBA is the global umbrella body for generic and biosimilar medicines associations. While its members are national generic associations rather than bulk drug bodies, it is a broad peer in international pharmaceutical trade and policy advocacy.
• Synthetic Organic Chemical Manufacturers Association (SOCMA): SOCMA is a US-based trade association serving the specialty and fine chemical manufacturing industry, including APIs. It is a broad incumbent peer covering adjacent chemical manufacturing trade association services in the North American market.

Regional players

• European Fine Chemicals Group (EFCG): EFCG is the European fine chemicals industry group representing API manufacturers in Europe under CEFIC. It is a regional peer that serves a similar trade association function for European bulk drug manufacturers and engages on regulatory and quality standards.
• Bulk Drug Industry Association (China): The China Pharmaceutical Industry Association (CPIA) and related China bulk drug industry bodies are regional peers serving a parallel function for Chinese API manufacturers, the primary global competitors to Indian bulk drug producers.

Others

• CPhI (Informa Markets): CPhI is the leading global pharmaceutical exhibition and media brand, running CPhI India and other events. It is an ecosystem peer/adjacent infrastructure provider with which BDMAI partners for international exhibition participation.

Emerging players

• National Pharmaceutical Pricing Authority (NPPA) ecosystem partners — Indian Pharmaceutical Alliance (IPA-India): The Indian Pharmaceutical Alliance is a forum of large Indian pharma companies, with overlapping membership with BDMAI members. It is an emerging player in policy advocacy that competes for mindshare and influence with BDMAI among the largest API/formulation manufacturers.

Direct peers

• Indian Drug Manufacturers' Association (IDMA): IDMA is the largest all-India body representing the Indian pharmaceutical manufacturing industry, including formulations and APIs. It is the closest functional peer to BDMAI in terms of advocacy, regulatory engagement, and member services, though its scope is broader (formulations plus bulk drugs).
• Organization of Pharmaceutical Producers of India (OPPI): OPPI represents research-based pharmaceutical companies in India and engages on policy, regulatory, and IP issues. It is a direct peer in the pharmaceutical industry association space, though skewed toward multinational and branded manufacturers rather than bulk drug producers.
• Pharmaceuticals Export Promotion Council of India (Pharmexcil): Pharmexcil is the official export promotion body for the Indian pharmaceutical industry, set up by the Ministry of Commerce. It is a direct peer that overlaps with BDMAI on export market access, B2B platforms, and international exhibition participation (IPHEX).
• Indian Pharmaceutical Association (IPA): IPA is the national professional body of pharmacists in India, focused on pharmacy education, practice, and pharmaceutical sciences. It is a peer in the broader pharma association ecosystem where BDMAI also operates, with overlapping regulatory advocacy mandates.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@bdmai-y1r?si=vC_OqXYnAv3APX4P
• Facebookfacebook.com/bdmaihyderabad
• LinkedInlinkedin.com/company/bulk-drugs-manufacturers-association

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bulk Drugs Manufacturers Association